Evolent Health (EVH)

• Market cap: $1.04B
• 1 day: 0.11%
• 5 days: -4.85%
• 1 month: -4.33%
• 3 months: -12.75%
• 6 months: -28.50%
• Year to date: -23.15%
• 1 year: -62.12%
• 5 years: 10.79%
• 10 years: -53.18%
• Sector: Healthcare
• Industry: Health Information Services

About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Employees: 4,500

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

58% more call options, than puts

Call options by funds: $20.2M | Put options by funds: $12.8M

29% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 69

5.16% less ownership

Funds ownership: 110.18% [Q3] → 105.02% (-5.16%) [Q4]

8% less funds holding

Funds holding: 260 [Q3] → 238 (-22) [Q4]

17% less first-time investments, than exits

New positions opened: 58 | Existing positions closed: 70

62% less capital invested

Capital invested by funds: $3.62B [Q3] → $1.38B (-$2.24B) [Q4]

71% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 2 (-5) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 36% upside
• Avg. target: $13.86 57% upside
• High target: $16 81% upside

7 analyst ratings

• positive: 7 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ryan MacDonald 53% 1-year accuracy 43 / 81 met price target	70% upside $15	Buy Reiterated	13 May 2025
UBS Kevin Caliendo 47% 1-year accuracy 8 / 17 met price target	70% upside $15	Buy Maintained	9 May 2025
JMP Securities Constantine Davides 45% 1-year accuracy 15 / 33 met price target	47% upside $13	Market Outperform Reiterated	28 Apr 2025
Truist Securities Jailendra Singh 20% 1-year accuracy 6 / 30 met price target	59% upside $14	Buy Maintained	10 Apr 2025
JP Morgan Anne Samuel 47% 1-year accuracy 16 / 34 met price target	36% upside $12	Overweight Maintained	10 Mar 2025